Lymphedema following taxane-based chemotherapy in women with early breast cancer.
Identifieur interne : 006D37 ( Ncbi/Merge ); précédent : 006D36; suivant : 006D38Lymphedema following taxane-based chemotherapy in women with early breast cancer.
Auteurs : Mi-Joung Lee [Australie] ; Jane Beith ; Leigh Ward ; Sharon KilbreathSource :
- Lymphatic research and biology [ 1557-8585 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Australie (épidémiologie), Bras (anatomopathologie), Cyclophosphamide (administration et posologie), Douleur (), Douleur (épidémiologie), Doxorubicine (administration et posologie), Femelle, Fluorouracil (administration et posologie), Humains, Incidence, Lymphoedème (), Lymphoedème (diagnostic), Lymphoedème (épidémiologie), Pronostic, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Stade de la tumeur, Tumeurs du sein (anatomopathologie), Tumeurs du sein (traitement médicamenteux), Épirubicine (administration et posologie), Études de suivi.
- MESH :
- administration et posologie : Cyclophosphamide, Doxorubicine, Fluorouracil, Épirubicine.
- anatomopathologie : Bras, Tumeurs du sein.
- diagnostic : Lymphoedème.
- effets indésirables : Protocoles de polychimiothérapie antinéoplasique.
- traitement médicamenteux : Tumeurs du sein.
- épidémiologie : Australie, Douleur, Lymphoedème.
- Adulte d'âge moyen, Douleur, Femelle, Humains, Incidence, Lymphoedème, Pronostic, Stade de la tumeur, Études de suivi.
- Wicri :
- geographic : Australie.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (adverse effects), Arm (pathology), Australia (epidemiology), Breast Neoplasms (drug therapy), Breast Neoplasms (pathology), Cyclophosphamide (administration & dosage), Doxorubicin (administration & dosage), Epirubicin (administration & dosage), Female, Fluorouracil (administration & dosage), Follow-Up Studies, Humans, Incidence, Lymphedema (chemically induced), Lymphedema (diagnosis), Lymphedema (epidemiology), Middle Aged, Neoplasm Staging, Pain (chemically induced), Pain (epidemiology), Prognosis.
- MESH :
- chemical , administration & dosage : Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil.
- geographic , epidemiology : Australia.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemically induced : Lymphedema, Pain.
- diagnosis : Lymphedema.
- drug therapy : Breast Neoplasms.
- epidemiology : Lymphedema, Pain.
- pathology : Arm, Breast Neoplasms.
- Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Neoplasm Staging, Prognosis.
Abstract
Taxanes can cause fluid accumulation by increasing extracellular fluid (ECF). Taxane-based regimens are standard of care for early breast cancer, but it is unknown whether they increase the risk of lymphedema. The aim of this study was to describe the incidence of lymphedema, generalized limb edema, and associated symptoms in women receiving adjuvant taxane-based chemotherapy.
DOI: 10.1089/lrb.2014.0030
PubMed: 25411764
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001201
- to stream PubMed, to step Curation: 001201
- to stream PubMed, to step Checkpoint: 001201
Links to Exploration step
pubmed:25411764Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lymphedema following taxane-based chemotherapy in women with early breast cancer.</title><author><name sortKey="Lee, Mi Joung" sort="Lee, Mi Joung" uniqKey="Lee M" first="Mi-Joung" last="Lee">Mi-Joung Lee</name><affiliation wicri:level="3"><nlm:affiliation>1 Faculty of Health Sciences, University of Sydney , Sydney, Australia .</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>1 Faculty of Health Sciences, University of Sydney , Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Beith, Jane" sort="Beith, Jane" uniqKey="Beith J" first="Jane" last="Beith">Jane Beith</name></author><author><name sortKey="Ward, Leigh" sort="Ward, Leigh" uniqKey="Ward L" first="Leigh" last="Ward">Leigh Ward</name></author><author><name sortKey="Kilbreath, Sharon" sort="Kilbreath, Sharon" uniqKey="Kilbreath S" first="Sharon" last="Kilbreath">Sharon Kilbreath</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25411764</idno><idno type="pmid">25411764</idno><idno type="doi">10.1089/lrb.2014.0030</idno><idno type="wicri:Area/PubMed/Corpus">001201</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001201</idno><idno type="wicri:Area/PubMed/Curation">001201</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001201</idno><idno type="wicri:Area/PubMed/Checkpoint">001201</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001201</idno><idno type="wicri:Area/Ncbi/Merge">006D37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lymphedema following taxane-based chemotherapy in women with early breast cancer.</title><author><name sortKey="Lee, Mi Joung" sort="Lee, Mi Joung" uniqKey="Lee M" first="Mi-Joung" last="Lee">Mi-Joung Lee</name><affiliation wicri:level="3"><nlm:affiliation>1 Faculty of Health Sciences, University of Sydney , Sydney, Australia .</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>1 Faculty of Health Sciences, University of Sydney , Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Beith, Jane" sort="Beith, Jane" uniqKey="Beith J" first="Jane" last="Beith">Jane Beith</name></author><author><name sortKey="Ward, Leigh" sort="Ward, Leigh" uniqKey="Ward L" first="Leigh" last="Ward">Leigh Ward</name></author><author><name sortKey="Kilbreath, Sharon" sort="Kilbreath, Sharon" uniqKey="Kilbreath S" first="Sharon" last="Kilbreath">Sharon Kilbreath</name></author></analytic><series><title level="j">Lymphatic research and biology</title><idno type="eISSN">1557-8585</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Arm (pathology)</term><term>Australia (epidemiology)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (pathology)</term><term>Cyclophosphamide (administration & dosage)</term><term>Doxorubicin (administration & dosage)</term><term>Epirubicin (administration & dosage)</term><term>Female</term><term>Fluorouracil (administration & dosage)</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Lymphedema (chemically induced)</term><term>Lymphedema (diagnosis)</term><term>Lymphedema (epidemiology)</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Pain (chemically induced)</term><term>Pain (epidemiology)</term><term>Prognosis</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Australie (épidémiologie)</term><term>Bras (anatomopathologie)</term><term>Cyclophosphamide (administration et posologie)</term><term>Douleur ()</term><term>Douleur (épidémiologie)</term><term>Doxorubicine (administration et posologie)</term><term>Femelle</term><term>Fluorouracil (administration et posologie)</term><term>Humains</term><term>Incidence</term><term>Lymphoedème ()</term><term>Lymphoedème (diagnostic)</term><term>Lymphoedème (épidémiologie)</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Stade de la tumeur</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Épirubicine (administration et posologie)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cyclophosphamide</term><term>Doxorubicin</term><term>Epirubicin</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Australia</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cyclophosphamide</term><term>Doxorubicine</term><term>Fluorouracil</term><term>Épirubicine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Bras</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Lymphedema</term><term>Pain</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Lymphedema</term><term>Pain</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Arm</term><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Australie</term><term>Douleur</term><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Douleur</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Lymphoedème</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Études de suivi</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Taxanes can cause fluid accumulation by increasing extracellular fluid (ECF). Taxane-based regimens are standard of care for early breast cancer, but it is unknown whether they increase the risk of lymphedema. The aim of this study was to describe the incidence of lymphedema, generalized limb edema, and associated symptoms in women receiving adjuvant taxane-based chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25411764</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2015</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2014</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-8585</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Lymphatic research and biology</Title><ISOAbbreviation>Lymphat Res Biol</ISOAbbreviation></Journal><ArticleTitle>Lymphedema following taxane-based chemotherapy in women with early breast cancer.</ArticleTitle><Pagination><MedlinePgn>282-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/lrb.2014.0030</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Taxanes can cause fluid accumulation by increasing extracellular fluid (ECF). Taxane-based regimens are standard of care for early breast cancer, but it is unknown whether they increase the risk of lymphedema. The aim of this study was to describe the incidence of lymphedema, generalized limb edema, and associated symptoms in women receiving adjuvant taxane-based chemotherapy.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Women (n=63) recruited after axillary surgery for early breast cancer were assessed prior to anthracycline-based, prior to taxane-based chemotherapy, and 3 weeks and 6 months after completing taxane-based chemotherapy. At each assessment, the inter-limb ECF ratios and intra-limb intracellular fluid to ECF ratios were determined using bioimpedance spectroscopy. Inter-limb arm volume ratios were calculated from arm circumferences measurements. Self-rated symptoms of swelling and pain in the arm on the side of surgery were recorded. In the 53 women who completed assessments, taxane-based chemotherapy increased the ECF volume in both upper and lower limbs, which was not observed after anthracycline-based chemotherapy. The arm on the side of surgery was preferentially affected, indicated by elevated ECF ratios at 3 weeks and 6 months after completing taxane-based chemotherapy with 32% and 23% meeting the criteria for lymphedema at these time-points, respectively. Edema resolved by 6 months following completion of chemotherapy except in the arm on the side of surgery.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incidence of lymphedema in the arm on the side of surgery following taxane-based chemotherapy was increased persisting at least 6 months after ceasing chemotherapy. However, generalized swelling in the legs and opposite arm resolved by 6 months after chemotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Mi-Joung</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>1 Faculty of Health Sciences, University of Sydney , Sydney, Australia .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beith</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Leigh</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kilbreath</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lymphat Res Biol</MedlineTA><NlmUniqueID>101163587</NlmUniqueID><ISSNLinking>1539-6851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3Z8479ZZ5X</RegistryNumber><NameOfSubstance UI="D015251">Epirubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015251" MajorTopicYN="N">Epirubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25411764</ArticleId><ArticleId IdType="doi">10.1089/lrb.2014.0030</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Nouvelle-Galles du Sud</li></region><settlement><li>Sydney</li></settlement></list><tree><noCountry><name sortKey="Beith, Jane" sort="Beith, Jane" uniqKey="Beith J" first="Jane" last="Beith">Jane Beith</name><name sortKey="Kilbreath, Sharon" sort="Kilbreath, Sharon" uniqKey="Kilbreath S" first="Sharon" last="Kilbreath">Sharon Kilbreath</name><name sortKey="Ward, Leigh" sort="Ward, Leigh" uniqKey="Ward L" first="Leigh" last="Ward">Leigh Ward</name></noCountry><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Lee, Mi Joung" sort="Lee, Mi Joung" uniqKey="Lee M" first="Mi-Joung" last="Lee">Mi-Joung Lee</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006D37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 006D37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25411764
|texte= Lymphedema following taxane-based chemotherapy in women with early breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25411764" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |